Search Results - "Shellenberger, Thomas D."

  • Showing 1 - 20 results of 20
Refine Results
  1. 1

    Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp by Guadagnolo, B. Ashleigh, Zagars, Gunar K., Araujo, Dejka, Ravi, Vinod, Shellenberger, Thomas D., Sturgis, Erich M.

    Published in Head & neck (01-05-2011)
    “…Background The aim of the present analysis was to retrospectively evaluate outcomes in patients with cutaneous angiosarcoma of the face/scalp treated…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Multidisciplinary Team Planning for Patients with Head and Neck Cancer by Shellenberger, Thomas D., DMD, MD, Weber, Randal S., MD

    “…The multidisciplinary team planning conference is critical in the evaluation and management of patients with head and neck cancer. The management is complex…”
    Get full text
    Journal Article
  4. 4

    High Rate of BRAF and RET/PTC Dual Mutations Associated with Recurrent Papillary Thyroid Carcinoma by Henderson, Ying C, Shellenberger, Thomas D, Williams, Michelle D, El-Naggar, Adel K, Fredrick, Mitchell J, Cieply, Kathleen M, Clayman, Gary L

    Published in Clinical cancer research (15-01-2009)
    “…Purpose: Papillary thyroid carcinoma (PTC), the most common thyroid malignancy, usually possesses BRAF mutation or rearranged in translation (RET)/PTC…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7

    BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells by SHELLENBERGER, Thomas D, WANG, Mary, CLAYMAN, Gary L, FREDERICK, Mitchell J, GUJRATI, Manu, JAYAKUMAR, Arumugam, STRIETER, Robert M, BURDICK, Marie D, IOANNIDES, Constantin G, EFFERSON, Clayton L, EL-NAGGAR, Adel K, ROBERTS, Dianna

    Published in Cancer research (Chicago, Ill.) (15-11-2004)
    “…BRAK/CXCL14 is a CXC chemokine constitutively expressed at the mRNA level in certain normal tissues but absent from many established tumor cell lines and human…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Cervical Tracheal Transection after Scarf Entanglement in a Go-Kart Engine by Seims, Aaron D., MD, Shellenberger, Thomas D., DMD, MD, Parrish, Gary A., MD, Lube, Matthew W., MD

    Published in The Journal of emergency medicine (01-07-2013)
    “…Abstract Background Tracheal disruption secondary to blunt force occurs infrequently. Most individuals suffering such an injury die before arriving at a…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12

    Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma by Clayman, Gary L., Shellenberger, Thomas D., Ginsberg, Lawrence E., Edeiken, Beth S., El-Naggar, Adel K., Sellin, Rena V., Waguespack, Steven G., Roberts, Dianna B., Mishra, Anupam, Sherman, Steven I.

    Published in Head & neck (01-09-2009)
    “…Background Despite the generally favorable prognosis of patients with papillary thyroid cancers, 10‐year recurrence rates for patients with stage I to III…”
    Get full text
    Journal Article
  13. 13

    Sarcomas of the head and neck region by Shellenberger, Thomas D., Sturgis, Erich M.

    Published in Current oncology reports (01-03-2009)
    “…Sarcomas of the head and neck are a heterogeneous group of rare malignancies with highly variable clinical presentation, pathologic classification, and…”
    Get full text
    Journal Article
  14. 14

    Headpin : A serpin with endogenous and exogenous suppression of angiogenesis by SHELLENBERGER, Thomas D, MAZUMDAR, Abhijit, HENDERSON, Ying, BRIGGS, Katrina, WANG, Mary, CHATTOPADHYAY, Chandrani, JAYAKUMAR, Arumugam, FREDERICK, Mitchell, CLAYMAN, Gary L

    Published in Cancer research (Chicago, Ill.) (15-12-2005)
    “…Headpin is a novel serine proteinase inhibitor (serpin) with constitutive mRNA expression in histologically normal oral mucosa but with lost or down-regulated…”
    Get full text
    Journal Article
  15. 15

    Quality Indicators in Head and Neck Operations: A Comparison With Published Benchmarks by Shellenberger, Thomas D, Madero-Visbal, Rafael, Weber, Randal S

    “…OBJECTIVE To investigate the reproducibility of quality indicators in the care of patients undergoing operations for head and neck cancer. DESIGN A review of…”
    Get full text
    Journal Article
  16. 16

    Neoadjuvant immunotherapy in clinical stage III melanoma: Real life experience in the community setting by Mahmoud, Fade, Gimbel, Mark, Toledo, Ryan, Abbott, Jordan, Shellenberger, Thomas D., Tomeh, Chafeek, Healy, Mark Andrew, Dave, Vishangi

    Published in Journal of clinical oncology (01-06-2024)
    “…e21556 Background: There is a paradigm shift in the management of clinical stages IIIB-IIID melanoma. Results from phase II clinical trials revealed higher…”
    Get full text
    Journal Article
  17. 17

    The impact of medical comorbidities on the quality of care for patients with head and neck cancer by Ernst, Brenda, Busowski, Mary T, Weber, Randal S., Shellenberger, Thomas D.

    Published in Journal of clinical oncology (20-05-2012)
    “…Abstract only e16030 Background: Objectively assessing the treatment of patients with cancer offers a basis for raising the standard of care. Quality…”
    Get full text
    Journal Article
  18. 18

    Abstract 4316: Suppression of Sp protein expression with Tolfenamic Acid inhibits oral Squamous Cell Carcinoma by Madero, Rafael A., Lee, Chriss M., Basha, Riyaz M., Abdelrahim, Maen A., Baker, Cheryl H., Shellenberger, Thomas D.

    Published in Cancer research (Chicago, Ill.) (15-04-2011)
    “…OBJECTIVE: Upregulation of members of the Sp protein family is associated with cell proliferation and metastasis in multiple cancer types. Tolfenamic acid (TA)…”
    Get full text
    Journal Article
  19. 19
  20. 20